Efficacy of CytoSorb®: a systematic review and meta-analysis
Pooled result · Mortality, all studiesResult — go to the resultRelative risk 1.07 95% CI 0.88–1.31Authors' conclusion
To date, there is no evidence for a positive effect of the CytoSorb® adsorber on mortality across a variety of diagnoses that justifies its widespread use in intensive care medicine.
Study context
- Population
- Patients with sepsis, CPB surgery, other severe illness, SARS-CoV-2 infection or recovery from cardiac arrest34 studies (12 RCTs)
- Participants
- 1,297 vs 1,314
- Comparison
- CytoSorb® adsorber vs control
- CytoSorb®n = 1,297
- Controlsn = 1,314reference
- Outcome
- Longest reported mortality
Methodological detailsrandom effects model, subgroup analyses, prospectively registered, All observational studies at moderate to serious risk of bias
- Random effects model
- Subgroup analyses
- Prospectively registered
- All observational studies at moderate to serious risk of bias
Pooled result
Mortality, all studies
Relative risk
1.07
95% CI 0.88–1.31
CytoSorb® vs Controls
RR 1.07 (95% CI 0.88–1.31)
As reported in the abstract
Further pooled results
| Outcome | RR (95% CI) | |
|---|---|---|
| Mortality, sepsis (subgroup) | 0.98 (0.74–1.31) | |
| Mortality, CPB surgery (subgroup) | 0.91 (0.64–1.29) | |
| Mortality, other severe illness (subgroup) | 0.95 (0.59–1.55) | |
| Mortality, SARS-CoV-2 (subgroup) | 1.58 (0.50–4.94) | |
| Mortality, cardiac arrest (subgroup)Significant survival advantage of untreated controls | 1.22 (1.02–1.46) | |
| 0.20.5125Relative risk (log scale) |
ICU LOS, lactate, IL-6 after treatment
- No significant differences
Original publication
Efficacy of CytoSorb®: a systematic review and meta-analysis. Crit Care. Published 31 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →